BMO Capital analyst Matthew Borsch said he would not overreact to a Politico report that Centene's pending acquisition of Fidelis health plan is in jeopardy due to a fight between the Archdiocese of New York and Governor Cuomo. The dispute may impact the deal timing, but both parties have more to gain than lose and he suspects the deal is still substantially more likely than not to get done, Borsch tells investors. The analyst, who said he would be a buyer on any weakness, keeps an Outperform rating on Centene, which he identifies as his favorite name in Managed Care.

Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here

Wells Fargo raised the firm's price target on Centene (CNC) to $93 from $89 and keeps an Overweight rating on the shares. The firm notes Florida intends to award Medicaid contracts to Centene, Elevance Health (ELV), Humana (HUM) and two provider-run plans. Clearly the most positive for Centene given recent disappointing RFP performance and likely most disappointing for Molina Healthcare (MOH) given expectation for share gains, Wells says.